Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
KALA 
Kala Pharmaceuticals Inc (KALA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: KALA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -51.33% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.49M USD | Price to earnings Ratio - | 1Y Target Price 15 |
Price to earnings Ratio - | 1Y Target Price 15 | ||
Volume (30-day avg) 25513 | Beta -2.2 | 52 Weeks Range 4.21 - 11.20 | Updated Date 04/1/2025 |
52 Weeks Range 4.21 - 11.20 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.67 |
Earnings Date
Report Date 2025-03-27 | When Before Market | Estimate -2.47 | Actual -1.2316 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -43.75% | Return on Equity (TTM) -430.96% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 24079532 | Price to Sales(TTM) 1.16 |
Enterprise Value 24079532 | Price to Sales(TTM) 1.16 | ||
Enterprise Value to Revenue 0.04 | Enterprise Value to EBITDA -0.16 | Shares Outstanding 6091180 | Shares Floating 2633911 |
Shares Outstanding 6091180 | Shares Floating 2633911 | ||
Percent Insiders 4.12 | Percent Institutions 58.58 |
Analyst Ratings
Rating 4.5 | Target Price 15 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kala Pharmaceuticals Inc
Company Overview
History and Background
Kala Pharmaceuticals Inc. was founded in 2009 and focused on developing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particle (MPP) technology. The company aimed to improve drug delivery to the eye.
Core Business Areas
- Ophthalmology: Focused on the discovery, development, and commercialization of therapies for eye diseases. This included prescription products.
Leadership and Structure
Kala Pharmaceuticals had a leadership team consisting of a CEO, CFO, CMO, and other executives. The organizational structure was typical of a publicly traded biotechnology company.
Top Products and Market Share
Key Offerings
- Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25%: Eysuvis is a corticosteroid indicated for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease. Competitors include Restasis (AGN), Xiidra (NOVN).
- Inveltys (loteprednol etabonate ophthalmic suspension) 1%: Inveltys is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. Competitors include Durezol (ALC), Pred Forte (AGN).
Market Dynamics
Industry Overview
The ophthalmology market is driven by an aging population and increasing prevalence of eye diseases. The market includes prescription drugs, over-the-counter products, and surgical procedures.
Positioning
Kala aimed to differentiate itself through its MPP technology, improving drug delivery and efficacy compared to traditional eye drops.
Total Addressable Market (TAM)
The global ophthalmology market is estimated in the billions of USD. Kala aimed to capture a portion of the market through its differentiated products. The exact positioning relative to the TAM is dependent on market penetration and competition which has a high degree of uncertainty.
Upturn SWOT Analysis
Strengths
- Proprietary MPP technology
- Approved products (Eysuvis, Inveltys)
Weaknesses
- Dependence on limited number of products
- Commercial execution challenges
- Financial constraints and liquidity
Opportunities
- Expanding indications for existing products
- Partnering with larger pharmaceutical companies
- Developing new formulations using MPP technology
Threats
- Competition from established pharmaceutical companies
- Generic entry for existing products
- Regulatory hurdles and clinical trial failures
Competitors and Market Share
Key Competitors
- AGN
- NOVN
- ALC
Competitive Landscape
Kala Pharmaceuticals faces strong competition from established pharmaceutical companies with larger sales forces and marketing budgets. The competitive environment includes prescription drugs.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Kala Pharmaceuticals experienced initial growth with the launch of its products but struggled with commercial execution and financial sustainability.
Future Projections: Future projections are uncertain given Kala Pharmaceutical's financial difficulties.
Recent Initiatives: Recent initiatives included cost-cutting measures and attempts to restructure the company.
Summary
Kala Pharmaceuticals is a company that focused on eye diseases with it's Eysuvis product to treat dry eyes. It has been facing significant financial and operational challenges, leading to its recent restructuring. It is competing with larger, more established pharmaceutical companies in a competitive market. The company's future prospects are highly uncertain given its current financial situation and it is likely that the company has ceased operations.
Similar Companies
- AGN
- NOVN
- ALC
Sources and Disclaimers
Data Sources:
- Company SEC filings
- Company website
- Industry reports
- Third-party financial data providers
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. The information is based on available data and may be subject to change. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kala Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Arlington, MA, United States | ||
IPO Launch date 2017-07-20 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 43 | Website https://www.kalarx.com |
Full time employees 43 | Website https://www.kalarx.com | ||
KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.